Is RVMD or ERAS more profitable?

Erasca's return on equity of -38.43% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Revolution Medicines N/A -88.20% -57.85% Erasca N/A -38.43% -32.05%

Does the media refer more to RVMD or ERAS?

In the previous week, Revolution Medicines had 12 more articles in the media than Erasca. MarketBeat recorded 14 mentions for Revolution Medicines and 2 mentions for Erasca. Revolution Medicines' average media sentiment score of 0.57 beat Erasca's score of 0.54 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or ERAS?

In the previous week, United Therapeutics had 39 more articles in the media than Erasca. MarketBeat recorded 41 mentions for United Therapeutics and 2 mentions for Erasca. Erasca's average media sentiment score of 0.54 beat United Therapeutics' score of 0.42 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 13 Very Positive mention(s) 11 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Erasca 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ERAS or ASND?

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Erasca. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 2 mentions for Erasca. Erasca's average media sentiment score of 0.54 beat Ascendis Pharma A/S's score of -0.02 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, EXEL or ERAS?

Exelixis has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.23 $782.57M $3.18 18.35 Erasca N/A N/A -$124.55M -$0.95 N/A

Is EXEL or ERAS more profitable?

Exelixis has a net margin of 35.33% compared to Erasca's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Erasca N/A -38.43% -32.05%

Does the media favor EXEL or ERAS?

In the previous week, Exelixis had 2 more articles in the media than Erasca. MarketBeat recorded 4 mentions for Exelixis and 2 mentions for Erasca. Exelixis' average media sentiment score of 0.74 beat Erasca's score of 0.54 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or ERAS?

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Erasca. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 2 mentions for Erasca. Erasca's average media sentiment score of 0.54 beat Halozyme Therapeutics' score of 0.19 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Erasca (ERAS) Competitors

$14.74 +0.16 (+1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$14.72 -0.02 (-0.14%)

As of 07:36 PM Eastern

Compare

ERAS vs. RVMD, UTHR, ASND, EXEL, and HALO

Should you buy Erasca stock or one of its competitors? Erasca's main competitors and comparable companies include Revolution Medicines (RVMD), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Exelixis (EXEL), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Erasca compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Revolution Medicines has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Erasca has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Erasca has lower revenue, but higher earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,820.32	-$1.13B	-$8.82	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

In the previous week, Revolution Medicines had 12 more articles in the media than Erasca. MarketBeat recorded 14 mentions for Revolution Medicines and 2 mentions for Erasca. Revolution Medicines' average media sentiment score of 0.57 beat Erasca's score of 0.54 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines presently has a consensus target price of $234.33, indicating a potential upside of 13.53%. Erasca has a consensus target price of $22.09, indicating a potential upside of 48.54%. Given Erasca's higher probable upside, analysts clearly believe Erasca is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Erasca's return on equity of -38.43% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Erasca	N/A	-38.43%	-32.05%

Summary

Revolution Medicines beats Erasca on 8 of the 15 factors compared between the two stocks.

How does Erasca compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

United Therapeutics has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.37	$1.33B	$27.95	19.57
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

United Therapeutics has a net margin of 41.56% compared to Erasca's net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Erasca	N/A	-38.43%	-32.05%

In the previous week, United Therapeutics had 39 more articles in the media than Erasca. MarketBeat recorded 41 mentions for United Therapeutics and 2 mentions for Erasca. Erasca's average media sentiment score of 0.54 beat United Therapeutics' score of 0.42 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	13 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 14.2% of Erasca shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

United Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Erasca has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

United Therapeutics currently has a consensus target price of $621.00, indicating a potential upside of 13.56%. Erasca has a consensus target price of $22.09, indicating a potential upside of 48.54%. Given Erasca's higher probable upside, analysts plainly believe Erasca is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

United Therapeutics beats Erasca on 11 of the 15 factors compared between the two stocks.

How does Erasca compare to Ascendis Pharma A/S?

Erasca (NASDAQ:ERAS) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Ascendis Pharma A/S has a net margin of 70.99% compared to Erasca's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Erasca has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Erasca. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 2 mentions for Erasca. Erasca's average media sentiment score of 0.54 beat Ascendis Pharma A/S's score of -0.02 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Erasca has higher earnings, but lower revenue than Ascendis Pharma A/S. Erasca is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Ascendis Pharma A/S	$814.57M	17.26	-$258M	$12.89	17.49

Erasca currently has a consensus target price of $22.09, suggesting a potential upside of 48.54%. Ascendis Pharma A/S has a consensus target price of $310.75, suggesting a potential upside of 37.85%. Given Erasca's higher probable upside, analysts plainly believe Erasca is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Ascendis Pharma A/S beats Erasca on 11 of the 16 factors compared between the two stocks.

How does Erasca compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Exelixis has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Erasca has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Exelixis presently has a consensus price target of $50.29, suggesting a potential downside of 13.83%. Erasca has a consensus price target of $22.09, suggesting a potential upside of 48.54%. Given Erasca's stronger consensus rating and higher probable upside, analysts clearly believe Erasca is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Exelixis has a net margin of 35.33% compared to Erasca's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Erasca	N/A	-38.43%	-32.05%

In the previous week, Exelixis had 2 more articles in the media than Erasca. MarketBeat recorded 4 mentions for Exelixis and 2 mentions for Erasca. Exelixis' average media sentiment score of 0.74 beat Erasca's score of 0.54 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Exelixis has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.23	$782.57M	$3.18	18.35
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Summary

Exelixis beats Erasca on 11 of the 16 factors compared between the two stocks.

How does Erasca compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Halozyme Therapeutics presently has a consensus price target of $91.20, indicating a potential downside of 16.18%. Erasca has a consensus price target of $22.09, indicating a potential upside of 48.54%. Given Erasca's stronger consensus rating and higher possible upside, analysts plainly believe Erasca is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Halozyme Therapeutics has a net margin of 24.86% compared to Erasca's net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Erasca	N/A	-38.43%	-32.05%

Halozyme Therapeutics has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.84	$316.89M	$3.35	32.48
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

In the previous week, Halozyme Therapeutics had 5 more articles in the media than Erasca. MarketBeat recorded 7 mentions for Halozyme Therapeutics and 2 mentions for Erasca. Erasca's average media sentiment score of 0.54 beat Halozyme Therapeutics' score of 0.19 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Erasca has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 14.2% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Halozyme Therapeutics beats Erasca on 11 of the 15 factors compared between the two stocks.

Get Erasca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERAS vs. The Competition

Export

Metric	Erasca	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.10B	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.65%	2.54%	16.76%
P/E Ratio	-15.52	12.93	273.67	26.04
Price / Sales	N/A	1,305.45	611.82	91.49
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	14.04	16.63	10.92	6.30
Net Income	-$124.55M	-$22.67M	$3.50B	$361.43M
7 Day Performance	3.44%	-3.05%	-2.11%	-1.67%
1 Month Performance	-9.96%	-10.75%	-6.34%	-3.94%
1 Year Performance	592.02%	21.11%	8.81%	2.77%

Erasca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERAS Erasca	2.2011 of 5 stars	$14.74 +1.1%	$22.09 +49.9%	+559.7%	$5.10B	N/A	N/A	103
RVMD Revolution Medicines	3.029 of 5 stars	$204.97 +2.6%	$230.15 +12.3%	+349.0%	$42.84B	$11.58M	N/A	883	Insider Trade Analyst Revision
UTHR United Therapeutics	3.9213 of 5 stars	$475.45 +0.7%	$621.00 +30.6%	+30.4%	$20.25B	$3.18B	17.01	1,400	Trending News Analyst Forecast Insider Trade
ASND Ascendis Pharma A/S	4.7691 of 5 stars	$225.60 -2.2%	$310.75 +37.7%	+11.4%	$14.39B	$814.57M	17.50	1,189
EXEL Exelixis	3.1568 of 5 stars	$58.16 +0.4%	$50.29 -13.5%	+40.6%	$14.36B	$2.32B	18.29	1,077

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERAS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Erasca (ERAS) Competitors

ERAS vs. RVMD, UTHR, ASND, EXEL, and HALO

How does Erasca compare to Revolution Medicines?

Summary

How does Erasca compare to United Therapeutics?

Summary

How does Erasca compare to Ascendis Pharma A/S?

Summary

How does Erasca compare to Exelixis?

Summary

How does Erasca compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Erasca (ERAS) Competitors

ERAS vs. RVMD, UTHR, ASND, EXEL, and HALO

How does Erasca compare to Revolution Medicines?

Which has more risk & volatility, RVMD or ERAS?

Do insiders and institutionals believe in RVMD or ERAS?

Which has stronger earnings & valuation, RVMD or ERAS?

Does the media refer more to RVMD or ERAS?

Do analysts prefer RVMD or ERAS?

Is RVMD or ERAS more profitable?

Summary

How does Erasca compare to United Therapeutics?

Which has higher earnings & valuation, UTHR or ERAS?

Is UTHR or ERAS more profitable?

Does the media favor UTHR or ERAS?

Do institutionals & insiders believe in UTHR or ERAS?

Which has more volatility & risk, UTHR or ERAS?

Do analysts prefer UTHR or ERAS?

Summary

How does Erasca compare to Ascendis Pharma A/S?

Is ERAS or ASND more profitable?

Which has more volatility and risk, ERAS or ASND?

Do insiders & institutionals have more ownership in ERAS or ASND?

Does the media favor ERAS or ASND?

Which has higher valuation and earnings, ERAS or ASND?

Do analysts prefer ERAS or ASND?

Summary

How does Erasca compare to Exelixis?

Which has more volatility and risk, EXEL or ERAS?

Do analysts rate EXEL or ERAS?

Is EXEL or ERAS more profitable?

Does the media favor EXEL or ERAS?

Do institutionals and insiders believe in EXEL or ERAS?

Which has higher valuation and earnings, EXEL or ERAS?

Summary

How does Erasca compare to Halozyme Therapeutics?

Do analysts recommend HALO or ERAS?

Is HALO or ERAS more profitable?

Which has preferable valuation and earnings, HALO or ERAS?

Does the media prefer HALO or ERAS?

Which has more volatility and risk, HALO or ERAS?

Do institutionals and insiders believe in HALO or ERAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools